Performance characteristics of the 2022 ACR/EULAR classification criteria for giant cell arteritis*
| Patient subset | Total no patients (no GCA patients) | Sensitivity (95% CI) | Specificity (95% CI) | AUC (95% CI) |
| Development data set | 1054 (518) | 84.8 (81.4 to 87.7) | 95.0 (92.8 to 96.7) | 0.90 (0.88 to 0.92) |
| Validation data set | 451 (238) | 87.0 (82.0 to 91.0) | 94.8 (91.0 to 97.4) | 0.91 (0.88 to 0.94) |
| Biopsy‐proven GCA† | 1104 (355) | 100.0 (99.0 to 100.0) | 94.9 (93.1 to 96.4) | 0.97 (0.97 to 0.98) |
| Large‐vessel GCA‡ | 873 (124) | 55.7 (46.5 to 64.6) | 94.9 (93.1 to 96.4) | 0.75 (0.71 to 0.80) |
*Performance characteristics were tested in the subsets using the combined development and validation data sets to maximise sample size.
†Definite vasculitis on temporal artery biopsy (TAB).
‡Involvement of the aorta or its branch arteries on imaging, without vasculitis on TAB.
ACR, American College of Rheumatology; AUC, area under the curve; GCA, giant cell arteritis.